Instituto Butantan and Merck have licensed certain rights from National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health, for the development of live attenuated tetravalent vaccines. Instituto Butantan's dengue vaccine candidate, TV003, is currently being evaluated in a large Phase 3 study in Brazil.
Under the agreement, Merck and Instituto Butantan have agreed to collaborate to share clinical data and other learnings from their respective dengue vaccine development programmes, both derived from licensed materials from the NIAID.
Instituto Butantan will receive a USD 26m upfront payment from Merck and is eligible to receive up to USD 75m for the achievement of certain milestones related to the development and commercialisation of Merck's investigational vaccine as well as potential royalties on sales. Instituto Butantan will retain responsibility for the manufacturing and commercialization of their investigational vaccine, TV003, in Brazil.
The agreement builds upon a productive long-term collaboration between MSD Brazil and Instituto Butantan, initiated in 2012, for human papillomavirus and Hepatitis-A vaccine products.
Dengue fever is a mosquito-borne disease that occurs in tropical and subtropical areas of the world. Mild dengue fever is characterized by a high fever, rash, and muscle and joint pain.
A severe form of dengue fever, (dengue hemorrhagic fever) can cause severe bleeding, a sudden drop in blood pressure and death. The World Health Organization has estimated that up to 400 m dengue infections occur annually, resulting in 500,000 hospitalisations.
Scientists in the Laboratory of Infectious Diseases at the NIAID of the NIH engineered a candidate live attenuated tetravalent vaccine against the dengue virus. NIAID then supported the development of the candidate vaccine through a series of clinical trials.
Instituto Butantan is sponsoring a placebo-controlled, double blind, multi-center Phase 3 trial evaluating a single dose of LATV produced at the institute in Sao Paulo.
The Phase 3 trial aims to enroll almost 17,000 healthy people aged 2 to 59 years in 15 cities.
All participants will be monitored for five years through a combination of in-person visits to the health clinic and telephone or text communications from the investigators.
The goal of the trial is to determine the efficacy of the vaccine for preventing dengue, and importantly to provide additional information about its safety. The principal investigator is Dr. Esper Kallas, for the University of Sao Paolo.
Instituto Butantan is the main producer of immunobiological products and vaccines in Brazil. Instituto Butantan carries out scientific missions domestically and abroad through the Pan American Health Organization, the World Health Organization, UNICEF and the United Nations.
The Institute collaborates with other agencies of the São Paulo State Secretariat of Health and the Brazilian Ministry of Health for the improvement of overall health in Brazil.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100